Finance
“Moderna shares dropped as much as 25% on Thursday following the leak of partial data on its cancer vaccine developed with Merck.”
Plain restatementOn Thursday 22 October 2026, Moderna's share price fell by up to approximately 25% at its intraday low, after partial Phase 3 data for the Moderna/Merck personalized cancer vaccine was published online ahead of its scheduled release.
General information only - not financial advice.
This checks out. Moderna's stock closed on Wednesday 21 October 2026 at $245.81, then on Thursday 22 October it traded as low as $180.80, about 26% below the prior close, before ending the day at $202.63, down 17.57%. So a fall of "as much as 25%" during the session is correct, though the day finished with a smaller loss of about 18%. The trigger is well documented: Phase 3 melanoma data for the Moderna and Merck vaccine intismeran autogene was due to be presented at a conference on Saturday 24 October, but it appeared on a medical news site around midday on Thursday, after which the embargo was lifted and the companies published the full results. The 42% reduction in risk of recurrence or death, in patients with completely resected stage IIB-IV melanoma, matches the companies' own published release exactly. One part of the caption is less settled: whether the results were positive relative to Wall Street expectations is described differently across outlets, with some reporting that certain data points fell short of what investors had hoped for. All figures here are as of 22 to 23 October 2026 and share prices change constantly. General information only, not financial advice.
[drifted from the evidence:] Moderna shares dropped as much as 25% on Thursday [drifted from the evidence:] following the leak of partial data [drifted from the evidence:] on its cancer vaccine [drifted from the evidence:] developed with Merck.
On Thursday [added by the neutral restatement:] 22 October 2026, Moderna's share price fell by up to approximately 25% at its intraday low, after partial [added by the neutral restatement:] Phase 3 data [added by the neutral restatement:] for the Moderna/Merck personalized cancer vaccine [added by the neutral restatement:] was published online ahead of its scheduled release.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- Moderna's share price fell sharply on Thursday 22 October 2026. Measured from Wednesday's $245.81 close, the session low of $180.80 was 26.4% lower, so a statement that shares fell "as much as 25%" is supported by the session data as of 2026-10-22.
- The fall followed the early online publication of Phase 3 data that was under embargo until a Saturday 24 October 2026 ESMO presentation.
- The vaccine is developed jointly by Moderna and Merck, and the leaked and later released data concerned the INTerpath-001 melanoma trial.
- The 42% figure in the caption matches the companies' own release exactly, including its scope: patients with completely resected stage IIB-IV melanoma, comparing intismeran plus Keytruda against Keytruda alone, at a median follow-up of 24.6 months.
- Merck shares also fell on the day, by a much smaller amount than Moderna's.
- Trading in Moderna shares was briefly halted for volatility during the session.
- No distortion identified in the primary claim. The wording "as much as 25%" correctly signals an intraday extreme rather than a closing change, and the session data supports it. A reader who skims it as "the stock ended the day 25% lower" would be wrong: the close was 17.57% down as of 2026-10-22. That gap sits in the reader's inference, not in the claim's wording.
- Whether the full data was "positive relative to Wall Street expectations," as the caption states, is contested across coverage rather than settled. One trade outlet reported that both companies' shares fell after some data points missed investor expectations. Another headlined a section on the results landing at the low end of investor expectations. The companies' own release reports statistically significant benefit on both endpoints; how that compared with buy-side expectations is a judgment, not a measurement.
- The causal link between the leak and the size of the move is an attribution made in the coverage rather than something the price data can establish. Several commentaries attribute the selloff to positioning after a very large year-to-date run rather than to the leak itself.
- The identity and route of the leak are reported but not formally established. Reuters-sourced coverage names the site where the data appeared and notes it was removed; no party has published a finding on how the embargo broke.
- Whether the exact intraday trough was 25% or closer to 26% varies slightly by data provider and by whether the measurement is against the prior close or the session open.
Moderna closed Wednesday 21 October 2026 at $245.81. In Thursday 22 October 2026 trading the stock opened at $240.13, reached a high of $241.26 and a low of $180.80, and closed at $202.63. The low is 26.4% below Wednesday's close, and the close is 17.57% below it. Trading in Moderna shares was briefly halted for volatility that day after reports of a partial data leak involving its personalized cancer vaccine, and the stock closed at $202.63, down 17.57%. One markets desk reported the stock fell as much as 26% before closing down more than 17%, its worst day since 20 August. On the leak itself: the results appeared on the medical news website Oncology Central around 12:30 p.m. ET and were taken down shortly afterwards, having been scheduled for presentation at the ESMO Congress on Saturday. The co-sponsors released the findings following an embargo break ahead of the 2026 ESMO Congress; the results were not scheduled to be shared until a Presidential Session on Saturday 24 October, but a cancer news site prematurely published an article covering the embargoed data, after which the conference lifted the embargo and the companies sent out a news release. The scheduled slot was confirmed in advance: LBA1 INTerpath-001 was listed for the Presidential Symposium on Saturday, October 24, 4:30 PM CEST / 10:30 AM EDT. On the underlying result, from the companies' own release: intismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001) compared to KEYTRUDA alone for patients with completely resected stage IIB-IV melanoma. At the primary pre-specified analysis (intention-to-treat), after a median follow-up of 24.6 months, the combination reduced the risk of recurrence or death by 42%. In a pre-specified sensitivity analysis, after six months, the reduction was 58% (piecewise HR=0.42 [95% CI, 0.30–0.58]). The vaccine is jointly developed: intismeran autogene (V940 or mRNA-4157) is an mRNA-based individualized neoantigen therapy being jointly developed by Merck and Moderna.
Complete reasoning
The reply is formatted for pasting into the thread where the claim is circulating.
Ask this case
Answers come only from the case file above; nothing is added.
Did Moderna's stock really fall 25% on that Thursday?
Yes, at its lowest point during the session on 22 October 2026, Moderna shares traded as low as $180.80, which is about 26.4% below Wednesday's close of $245.81. So the claim of a drop of 'as much as 25%' is supported by the intraday data.
Did the stock end the day down 25%?
No. Moderna closed at $202.63 that day, down about 17.57% from the prior close. The 25% figure refers to the lowest point during trading, not the final closing price.
What caused the drop?
Partial Phase 3 data on the Moderna/Merck personalized cancer vaccine, intismeran autogene, was published early on a medical news site before its scheduled presentation at the ESMO Congress on Saturday 24 October 2026. This led the conference to lift the embargo and the companies to release full results that day.
Was the leaked data actually bad news?
The companies' own release reported a statistically significant 42% reduction in risk of recurrence or death for patients with completely resected stage IIB-IV melanoma, which sounds positive. However, coverage is divided on whether the results met Wall Street's expectations, with some reports saying certain data points fell short of what investors hoped for.
Do we know exactly how or why the embargoed data leaked?
The investigation did not establish this. Reports name the site where the data briefly appeared and note it was taken down, but no party has published findings on how the embargo was broken.